| 2019年抗肿瘤新药研发热点回眸 |
| |
| 引用本文： | 石远凯,孙燕.2019年抗肿瘤新药研发热点回眸[J].科技导报(北京),2020,38(1):77-81. |
| |
| 作者姓名： | 石远凯 孙燕 |
| |
| 作者单位： | 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院内科, 抗肿瘤分子靶向药物临床研究北京市重点实验室, 北京 100021 |
| |
| 摘 要： | 恶性肿瘤是严重威胁人们健康最主要的慢性非传染性疾病，因此抗肿瘤新药研发成为新药研发的重点领域。近年来随着国家政策扶持和经济社会的持续发展，中国自主研发抗肿瘤新药的能力不断提高。2019年，一些新的国产抗肿瘤新药上市并开始临床应用，给患者提供了更多的治疗选择。本文从生物类似药、免疫治疗药物、靶向药物及抗血管生成药物等方面盘点了2019年上市的部分抗肿瘤新药的研究成果。
|
| 关 键 词： | 肿瘤 内科治疗 抗肿瘤新药 |
| 收稿时间： | 2020-01-02 |
Hotspots of new antitumor drugs in 2019 |
| |
| SHI Yuankai,SUN Yan.Hotspots of new antitumor drugs in 2019[J].Science & Technology Review,2020,38(1):77-81. |
| |
| Authors: | SHI Yuankai SUN Yan |
| |
| Institution: | Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China |
| |
| Abstract: | The research and development of new anti-tumor drugs is the key field of new drug research and development. In recent years, with the support of national policies and the sustainable development of economy and society, China's ability to independently develop new anti-tumor drugs has been continuously improved. In 2019, some new domestic anti-tumor drugs were used clinically, providing more treatment options for patients. In this paper, we review the research results of some new antitumor drugs launched in 2019 market. |
| |
| Keywords: | tumour internal medicine treatment new anti-tumor drugs |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《科技导报(北京)》浏览原始摘要信息 |
| 点击此处可从《科技导报(北京)》下载免费的PDF全文 |
